Jump to navigation Jump to search
Zotepine Wiki Str.png
Clinical data
Trade namesZoleptil
AHFS/Drugs.comInternational Drug Names
Routes of
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability7-13% (Oral)[1]
MetabolismN-desmethylation to norzotepine (30-40%)[1]
Elimination half-life13.7-15.9 hours, 12 hours (Norzotepine)[1]
Excretion17% (Urine)[1]
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass331.86
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Zotepine


Most recent articles on Zotepine

Most cited articles on Zotepine

Review articles on Zotepine

Articles on Zotepine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Zotepine

Images of Zotepine

Photos of Zotepine

Podcasts & MP3s on Zotepine

Videos on Zotepine

Evidence Based Medicine

Cochrane Collaboration on Zotepine

Bandolier on Zotepine

TRIP on Zotepine

Clinical Trials

Ongoing Trials on Zotepine at Clinical Trials.gov

Trial results on Zotepine

Clinical Trials on Zotepine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Zotepine

NICE Guidance on Zotepine


FDA on Zotepine

CDC on Zotepine


Books on Zotepine


Zotepine in the news

Be alerted to news on Zotepine

News trends on Zotepine


Blogs on Zotepine


Definitions of Zotepine

Patient Resources / Community

Patient resources on Zotepine

Discussion groups on Zotepine

Patient Handouts on Zotepine

Directions to Hospitals Treating Zotepine

Risk calculators and risk factors for Zotepine

Healthcare Provider Resources

Symptoms of Zotepine

Causes & Risk Factors for Zotepine

Diagnostic studies for Zotepine

Treatment of Zotepine

Continuing Medical Education (CME)

CME Programs on Zotepine


Zotepine en Espanol

Zotepine en Francais


Zotepine in the Marketplace

Patents on Zotepine

Experimental / Informatics

List of terms related to Zotepine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Zotepine (brand names: Losizopilon (JP), Lodopin (ID, JP), Setous (JP), Zoleptil (CZ, PT, TR, UK†); where † indicates a formulation that has been discontinued) is an atypical antipsychotic drug indicated for acute and chronic schizophrenia. It has been used in Germany since 1990 (although it has been discontinued in Germany) and Japan since 1982.

Zotepine is not approved for use in the United States, United Kingdom, Australia, Canada or New Zealand.[2]

Medical Uses

Zotepine's primary use is as a treatment for schizophrenia[3] although clinical trials have been conducted (with positive results) into its efficacy as an antimanic agent in patients with acute bipolar mania.[4][5][6]

Side effects

Unknown Frequency[1][3]


The antipsychotic effect of zotepine is thought to be mediated through antagonist activity at dopamine and serotonin receptors. Zotepine has a high affinity for the D1 and D2 receptors. It also affects the 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7 receptors.[8] In addition, its active metabolite, norzotepine, serves as a potent norepinephrine reuptake inhibitor.[9]

Macromolecule (Receptor or transporter protein) Ki [nM][8]
SERT 151
NET 530
DAT 3621
5-HT1A 470.5
5-HT1B 59.5
5-HT1D 119
5-HT1E 700
5-HT2A 2.7
5-HT2C 2.6
5-HT3 472
5-HT5A 29
5-HT6 6
5-HT7 12
α1A 7
α1B 5
α2A 180
α2B 5.35
α2C 106
M1 18
M2 140
M3 73
M4 77
M5 260
D1 71
D2 25
D2S 5.4
D2L 11
D3 6.4
D4 18
D5 248
H1 3.21
H2 500
H4 1977


The most common dosage used is 150 mg daily. It is suggested that zotepine therapy starts at 75 mg to 150 mg divided into three daily doses. Some people may need to have their dosage increased to 300 mg.[2]

Zotepine Pills.png


  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Truven Health Analytics, Inc. DRUGDEX® System (Internet) [cited 2013 Jun 25]. Greenwood Village, CO: Thomsen Healthcare; 2013.
  2. 2.0 2.1 2.2 "Zotepine". Martindale: The Complete Drug Reference. Royal Pharmaceutical Society of Great Britain. 16 August 2013. Retrieved 2 November 2013.
  3. 3.0 3.1 3.2 3.3 British National Formulary 58. British Medical Association and Royal Pharmaceutical Society of Great Britain; 2009.
  4. Chan, HY; Jou, SH; Juang, YY; Chang, CJ; Chen, JJ; Chen, CH; Chiu, NY (April 2010). "A single-blind, comparative study of zotepine versus haloperidol in combination with a mood stabilizer for patients with moderate-to-severe mania". Psychiatry and Clinical Neurosciences. 64 (2): 162–169. doi:10.1111/j.1440-1819.2010.02066.x. PMID 20447012.
  5. Harada, T; Otsuki, S (1986). "Antimanic effect of zotepine". Clinical Therapeutics. 8 (4): 406–414. PMID 3089626.
  6. Amann, B; Sterr, A; Mergl, R; Dittmann, S; Seemüller, F; Dobmeier, M; Orth, M; Schaefer, M; Grunze, H (October 2005). "Zotepine loading in acute and severely manic patients: a pilot study". Bipolar Disorders. 7 (5): 471–476. doi:10.1111/j.1399-5618.2005.00241.x. PMID 16176441.
  7. 7.0 7.1 7.2 Leucht, S; Cipriani, A; Spineli, L; Mavridis, D; Orey, D; Richter, F; Samara, M; Barbui, C; Engel, RR; Geddes, JR; Kissling, W; Stapf, MP; Lässig, B; Salanti, G; Davis, JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–962. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019.
  8. 8.0 8.1 National Institute of Mental Health (12 January 2011). "PDSD Ki Database". Chapel Hill (NC): University of North Carolina. Retrieved 2 November 2013.
  9. Shobo, M; Kondo, Y; Yamada, H; Mihara, T; Yamamoto, N; Katsuoka, M; Harada, K; Ni, K; Matsuoka, N (June 2010). "Norzotepine, a Major Metabolite of Zotepine, Exerts Atypical Antipsychotic-Like and Antidepressant-Like Actions through Its Potent Inhibition of Norepinephrine Reuptake" (PDF). The Journal of Pharmacology and Experimental Therapeutics. 333 (3): 772–781. doi:10.1124/jpet.110.166264. PMID 20223878.